Aptinyx’s Mid-Stage NMDA Receptor Fails to Hit Endpoints in Neuropathic Pain Study

Shares of Illinois-based Aptinyx have plunged more than 67 percent in premarket trading after the company announced its mid-stage treatment for painful diabetic peripheral neuropathy failed to show statistical significance. Aptinyx’s NYX-2925 is a novel NMDA receptor, which earned Fast Track designation from the U.S. Food and Drug Administration for the treatment of neuropathic pain associated with DPN.
Read more...

;